Thousand Oaks-based biotech giant Amgen announced positive results from patients receiving Prolia to treat inflammation Aug. 29.
In the study, Prolia, normally used to treat osteoporosis, hypercalcemia and bone cancer, was used to treat inflammation. The two-year study enrolled 795 patients to evaluate the safety of two 60 milligram doses of Prolia given under the skin compared to five milligram oral doses given daily.
Amgen said the results showed that Prolia led to significantly greater gains in bone mineral density at the lumbar spine and hip, both in patients receiving continuing inflammation therapy and in patients getting new inflammation therapy compared to a generic drug.
• Contact Philip Joens at [email protected]